In the increasingly complex world of healthcare, drug manufacturers find themselves under heightened scrutiny by federal regulators. Pursuant to Centers for Medicaid & Medicare Services (“CMS”) regulations, manufacturers are required to estimate the fair market value of certain services received when performing certain critical pricing calculations. Obtaining independent verification of the fair market value of services provided by distributors (sometimes referred to as “fee for service”) has become the prudent course of action for drug manufacturers. BVA specializes in providing accurate, and defensible fair market value analyses of service agreements to assist drug manufacturers in federal regulatory drug price reporting obligations.

Our CMS Reporting Valuation Services include:

  • Program Management

  • Chargeback Management

  • Call Center Setup and Support

  • Inventory Management

  • Shipping

  • Patient/Physician Information and Education Programs

  • Insurance Verification

  • Payment Term and Bad Debt Management

  • New Client Qualification including Credit Risk Assessment

  • Sales Data Reporting

How BVA Can Help

The partners at BVA have extensive experience assisting clients with these types of analyses, having performed valuations for many large pharmaceutical clients as well as a number of the largest biotechnology companies in the world. BVA has performed these projects in close cooperation with clients and their advisors, such as outside legal counsel, and often under attorney client privilege.